Sort
21,453 grants matching “tuberculosis”
A fully integrated assay and platform for detecting Clostridium difficile.
$1,000,000Bruce D Irvine · Claremont Biosolutions, Llc · R44 · FY2012 · AI
3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology
$1,000,000Jay Wyatt Warrick · Salus Discovery, Llc · R44 · FY2025 · AI
DAIDS RePORT India Consortium
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2016 · AI
HPMI: Host Pathogen Mapping Initiative
$1,000,000Nevan J Krogan · University Of California, San Francisco · U19 · FY2021 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic
$1,000,000Michael Lafleur · Arietis · R44 · FY2023 · AI
TB Diagnostics at the Point of Care
$1,000,000Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2018 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis
$1,000,000Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2022 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2015 · AI
A fully integrated assay and platform for detecting Clostridium difficile.
$1,000,000Tanya Marie Ferguson · Claremont Biosolutions, Llc · R44 · FY2014 · AI
Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen
$1,000,000Thomas W Tombler · Nanopin Technologies, Inc. · R44 · FY2022 · AI
NIAID DAIDS RePORT India
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2014 · AI
RePORT India
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2015 · AI
TB Diagnostics at the Point of Care
$1,000,000Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2020 · AI
A new class of broad-spectrum antibacterials for treating MDR infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2022 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) â Brazil Network
$1,000,000Timothy R Sterling · Vanderbilt University Medical Center · U01 · FY2025 · AI
VACCINE AND EVALUTION TREATMENT UNITS
$1,000,000Mark Joseph Mulligan · Emory University · N01 · FY2011 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) Consortia and Centers for AIDS Research (CFAR) Collaboration (RePORT- CFAR)
$1,000,000Michael Dignam · National Institute Of Allergy And Infectious Diseases · Y01 · FY2018 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2014 · AI
Closing -TB GAPs - for people living with HIV: TB Guidance for Adaptable Patient-Centered Service
$1,000,000Anna M Mandalakas · Baylor College Of Medicine · U01 · FY2021 · GH
A new class of broad-spectrum antibacterials for treating MDR infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2020 · AI
ENHANCING MODELS OF HIV, VIRAL HEPATITIS, STIs, AND TUBERCULOSIS TO INFORM AND IMPROVE PUBLIC HEALTH IMPACT
$1,000,000Patrick Sullivan · Emory University · U38 · FY2014 · PS
Regional Prospective Observational Research in Tuberculosis (RePORT) â Brazil Network
$1,000,000Timothy R Sterling · Vanderbilt University Medical Center · U01 · FY2023 · AI
Tuberculosis Research Materials and Vaccine Testing
$1,000,000Karen Dobos · Colorado State University · N01 · FY2010 · AI
AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM
$1,000,000Weill Medical College Of Cornell Univ · D43 · FY2003 · TW
TB Diagnostics at the Point of Care
$999,998Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2019 · AI